Overview

Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With Exemestane

Status:
Unknown status

Trial end date:
2021-01-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether biomarkers could be found to gain more insight in tumor characteristics in order to predict which patients will have a high chance of a long progression-free survival. Postmenopausal patients with advanced metastatic breast cancer who have progressed on anastrozole or letrozole will be eligible for this study.

Phase:

N/A

Details

Lead Sponsor:

VU University Medical Center

Collaborators:

Borstkanker Onderzoek Groep
Novartis

Treatments:

Everolimus
Exemestane
Sirolimus